Skip to main content

Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO



To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali® (Biogen Inc, Cambridge, USA).


Data from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs).


Eighty-three patients from the German JuMBO registry were treated with Benepali®. Of these, 74% had switched from Enbrel® (Pfizer Inc., NYC, USA) the originator of etanercept to Benepali® for cost reasons. Therapy survival of patients treated with Benepali® in comparison to Enbrel® in patients matched by significant parameters was comparable. Adverse events (AE) were reported in 25.3% and serious adverse events (SAE) in 9.6% of patients. Physicians rated no SAE causative related to Benepali®. The majority of SAEs were surgical/medical procedures and there was only one infection. All efficacy parameters (cJADAS-10, Physician Global Assessment, number of joints with active arthritis, patients’ overall well-being, pain, and HAQ) demonstrated improvement over 24 months (p-values were not significant). 9.6% of patients permanently discontinued Benepali® because of an AE.


Tolerability and effectiveness of the biosimilar Benepali® were satisfactory and therapy survival was comparable to the originator. Further data on therapy with biologics and biosimilars such as Benepali® must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term.


Juvenile idiopathic arthritis is the most common chronic rheumatic disease of childhood and a leading cause of short- and long-term disability [1]. The use of biologics has dramatically changed the therapeutic approach and associated outcomes. Since the approval of the first biologic, the BiKeR and JuMBO registers have provided data on long-term effectiveness and safety for therapy with DMARDs (disease-modifying anti-rheumatic drugs) in JIA [2,3,4,5].

Enbrel® (Pfizer Inc., NYC, USA) is still the biological agent most frequently used in Germany for JIA to achieve inactive disease or remission and to prevent long-term consequences [6].

The introduction of biosimilar DMARDs (bsDMARDs) has the potential to improve patient access to biologic therapy and to improve overall patient outcomes while they can lower the costs in health care [7]. This is why the German Joint Government Committee of physicians and health insurance companies has adopted guidelines for an economical way of prescribing biologics and biosimilars, which in the opinion of the Committee could lead up to savings of 37% compared with the use of original preparations [8]. Currently, there are three biosimilars approved for the etanercept originator Enbrel® in the EU: Benepali® (Biogen Inc, Cambridge, USA), Erelzi® (Novartis AG, Basel, Switzerland), and Nepexto® (Mylan Inc., Canonsburg, USA).

Since the therapy with a DMARD often has to be continued over a long period of time and may be crucial for the clinical outcome, data concerning the long-term safety and effectiveness of these substances are highly relevant. Data on the safety and effectiveness of bsDMARDs in JIA are still very sparse; there are still theoretical concerns about biosimilars regarding reduced efficacy, altered immunogenicity, and a different safety profile compared to the biooriginator [9].

Here we analyzed data concerning therapy adherence, safety, and clinical outcome for 83 patients from the JuMBO registry being treated with Benepali® to determine whether therapy is sufficient and safe.


Data sources

Data from JIA patients who reached 18 years of age were transferred from the JIA registry Biologics in Pediatric Rheumatology (BiKeR) [3] to its follow-up (FU) registry, Juvenile arthritis Methotrexate/Biologics long-term Observation (JuMBO) [10]. Both are ongoing multicenter prospective observational cohort studies. JuMBO was approved by the Ethics Committee of the Charité University Medicine Berlin and conducted in accordance with the Declaration of Helsinki.

Both registers aim to monitor the safety and effectiveness of cs and/or bDMARDs in patients with JIA [6, 11,12,13]. JuMBO monitors patients who have reached the age of 18 or left pediatric rheumatology care. Previous reports have extensively described the design of both registers [2, 10, 14, 15].


All patients with JIA according to the International League of Associations for Rheumatology criteria [16] who were enrolled in BiKeR in childhood, subsequently transferred to JuMBO, and ever treated with etanercept and the etanercept biosimilar Benepali® were considered for this study. Written informed consent was obtained from the patients (age ≥18 years).

Procedures and assessments

In JuMBO, patients are assessed every 6 months. The patient questionnaire includes socio-demographic characteristics, educational background, periods of incapacity for work, and hospitalizations. Patients rate their general well-being, disease activity, pain, and fatigue on an 11-point numerical rating scale (NRS, 0-10). In addition, the patient-relevant outcome instrument Health Assessment Questionnaire (HAQ) is used [17].

The doctor's questionnaire collects information on the current clinical condition of the patient (e.g., number of joints with swelling, range of motion limitations, tenderness or pain with motion (72-joint count)), erythrocyte sedimentation rate and C-reactive protein levels, and a physician’s global assessment of the patient’s disease activity (PhGA) on NRS. Current therapies, reasons for discontinuing them, and (serious) adverse events (AEs/SAEs) are documented as well.

Disease activity was assessed by the clinical Juvenile Arthritis Disease Activity Score (cJADAS-10) [18]. The cJADAS-10 cut-off values for defining the different states of disease activity were based on definitions by Consolaro et al. [19].

An AE is defined as any untoward medical occurrence associated with a pharmaceutical product during observation; a serious AE (SAE) results either in death, life-threatening illness, hospitalization/prolongation of hospitalization or medical or surgical intervention to prevent a serious outcome, results in persistent/significant disability or incapacity, or is a congenital anomaly or birth defect or a medically significant event determined by the responsible local physician that in their opinion jeopardized the health of the patient and required intervention to prevent one of the other outcomes listed [20]. AEs and SAEs were coded on the preferred term level with MedDRA (Medical Dictionary for Regulatory Activities) version 23.0.

Statistical analysis

Descriptive statistics included frequencies for categorical data and means, standard deviations, and median values for continuously distributed data. Therapy survival was investigated by Kaplan-Meier method. A matched etanercept originator (Enbrel®) control group was used in order to compare therapy survival with Benepali®. An Enbrel®-treated patient was matched to a Benepali® patient by number of bDMARD treatment courses in the past, JIA category, sex, ANA positivity, and disease duration at treatment start (± 3 years). The course of clinical parameters after treatment start with Benepali® was investigated in patients who switched from the etanercept originator to Benepali® for cost reasons by generalized linear mixed models. Time of follow-up was estimated with a linear spline approximation in order to model the heterogeneously distributed survey times in follow-up. All assessments within 3 months before start of Benepali® therapy and up to 3 months after the end of Benepali® therapy were used for the analyses. All models were adjusted for treatment duration with the etanercept originator before the switch to Benepali®. AE and SAE were reported by the number of patients with at least one such an event, number of events, and with crude incidence rates (IR) per 100 exposure years to Benepali®. 95% confidence intervals for incidence rates were calculated by Poisson rate confidence intervals for all AE and SAE. A p<0.05 was considered statistically significant. Data were analyzed using SAS V.9.4 software.


From a total of 1844 patients included in the German JuMBO registry, 83 patients were identified on June 23, 2021, who have ever been treated with Benepali®.

Patient characteristics

The patient characteristics are shown in Table 1. Most patients started Benepali® treatment after the age of 18 with a range of 16.6 to 38.2 years.

Table 1 Patient characteristics

Previous therapy

For only 6 (7.2%) patients Benepali® was the first-line biologic DMARD, the largest subgroup (n=31, 37.4%) had been treated with one bDMARD before switching to Benepali®. Over the course of the disease, the patients had received an average of 2.1 (SD 1.7, range 0 to 10) treatment courses with different biologic DMARDs prior to Benepali®. The last bDMARDs before starting Benepali® was Enbrel® (78.3%), adalimumab (3.6%), certolizumab (3.6%), baricitinib, Erelzi®, tocilizumab, ustekinumab, and tofacitinib (1.2% each).

Fifty-seven of 77 patients (74.0%) discontinued their previous bDMARD to switch from Enbrel® to Benepali® for cost reasons. Other reasons for discontinuation of prior bDMARD therapy included inactive disease (11.7%) and ineffectiveness (14.3%). Adverse events led to the termination of therapy in 5.2% and in 3.9% other reasons were causative.

Therapy survival

At the time of analysis, 54 of 83 (65.1%) patients were still on therapy while 29 patients had terminated therapy with Benepali®. The reasons for discontinuing therapy were diverse and included, e.g., ineffectiveness, the occurrence of an adverse event, and inactive disease in decreased order (Table 2).

Table 2 Reasons for termination of therapy with Benepali® (multiple answers were possible)

The Kaplan-Meier curve (Fig. 1A, n=83) for therapy adherence to Benepali® shows that after a follow-up period of 2 years about 60% of the patients are still under therapy, while after 4 years about 30% are still under therapy with Benepali®. In total, for 71 (of 83) Benepali®-treated patients, Enbrel®-treated patients could be identified and matched. Benepali® showed a comparable therapy survival as observed for Enbrel® (Fig. 1B).

Fig. 1
figure 1

A Therapy survival of patients treated with Benepali® (n=83) and B therapy survival of Benepali® in comparison to Enbrel® in patients matched by the number of bDMARD treatment courses in the past, JIA category, sex, ANA positivity, and disease duration at treatment start (± 3 years)


For 8 (9.6%) patients, the reason to terminate therapy with Benepali® was the occurrence of an adverse event. Upon closer inspection, any adverse event occurred in 21 patients (25.3%) while any serious adverse event occurred in 8 patients (9.6%). During the observation period of patients on Benepali® comprising 145 exposure years, 40 AEs and 10 SAEs were reported, resulting in an AE rate of 27.6 (95% CI, 19.7–37.6) and an SAE rate of 6.9 (95% CI, 3.3–12.7) per 100 patient-years. No SAE was rated by physicians to be causally related to Benepali®.

The majority of SAEs were surgical/medical procedures (Table 3). Interestingly, among the SAEs was only one infection. Under the reported AEs, infections were the largest subgroup with a rate of 8.28 per 100 patient-years (95% CI, 4.28–14.46).

Table 3 Serious adverse events under therapy with Benepali®


At the start of therapy with Benepali® in patients who switched from the etanercept originator to Benepali® for cost reasons, the mean cJADAS10 was 4.5 (95% CI, 3.6–5.4), PhGA 1.2 (95% CI, 0.9–1.5), and the mean number of active joints 0.4 (95% CI, 0.1–0.8). On a numerical rating scale (NRS 0-10) patients stated their overall well-being at 2.9 (95% CI, 2.4–3.3) and their pain at 3.1 (95% CI, 2.5-3.6). HAQ-score at therapy start was 0.18 (0.11–0.26). At Benepali® therapy start, 22.6% were in an inactive disease as assessed by cJADAS-10 (≤1), 85.3% had no active joint with arthritis, and 64.5% had no functional limitations (HAQ of 0). The course of the corresponding parameters in follow-up under Benepali® therapy can be seen in Fig. 2A–F. Clinical JADAS-10, PhGA, overall well-being, pain, and HAQ were in decline, which indicates that Benepali® was successful in therapy. The p-values were not significant; however, since the major reason for switch of therapy was cost-effectiveness, this could contribute to the insignificant improvement of disease activity in addition to the still limited number of patients reported.

Fig. 2
figure 2

A–F A Course of cJADAS-10, B Physician Global Assessment (PhGA), C Number of joints with active arthritis, D Patients overall well-being (NRS 0-10), E Pain (NRS 0-19), and F HAQ values over time (predicted means with 95% confidence intervals estimated by generalized linear mixed models,  p-value for change in parameters over 24 months)


The JuMBO Registry provides long-term data of adult patients with juvenile idiopathic arthritis being treated with biologicals. To our knowledge, we herein present the first cohort of adult patients with onset of rheumatic disease in childhood treated with the biosimilar Benepali®.

The majority of the patients analyzed were female, which fits in with the general gender distribution of JIA. The distribution of the JIA categories showed a comparatively high proportion of patients with RF-negative polyarthritis and extended oligoarthritis which indicates a rather severe JIA spectrum with a higher likelihood of therapy failure. All patients included in this study had received Benepali®, and two-thirds of them were still on this drug at the time of this analysis. The therapy survival of Benepali® was comparable to that observed for Enbrel®. This suggests a moderate side effect profile that can be tolerated by patients as well as a sufficient therapeutic effectiveness of Benepali®. This statement is also supported by the fact that ineffectiveness was the reason for discontinuing therapy in about 12% of the patients (especially considering the mentioned more severely affected patient cohort). In addition, a previous biological therapy before Benepali® was terminated in 14.3% of the patients due to inefficiency.

An SAE was the reason for discontinuing therapy with Benepali® for about 8% of patients. The rate of serious adverse events per 100 patient-years was about 1.2 times as high as the rate of patients on Enbrel® in a cohort of 155 patients from the JuMBO Registry analyzed by Minden et al. in 2012 [10] and about 1.8 times as high as the rate of patients on etanercept in a group of 2725 patients analyzed by Armaroli et al. in 2020 [5]. In 2021, Thiele et al. described an increased rate of local reactions in their cohort of JIA patients treated with etanercept biosimilars during childhood compared with the originator which is not being reflected in our cohort reporting adult patients only [9]. On closer inspection, the listed SAEs are heterogeneously distributed and commonly reported SAEs (for example anaphylaxis, cytopenias, hepatic events) were not reported [15]. In addition, compared to other cohorts, no new autoimmune disease or uveitis was reported in the cohort examined [21]. However, the observation period was also comparatively short for these events. No SAE was rated to be causally related to Benepali®. The SAEs are more likely related to the age of the patient and the long disease duration of the patient cohort: 2 of the 10 SAEs were due to pregnancies and 2 to joint operations. Overall, the frequency and severity of the SAE are tolerable. This fits in with the findings of Thiele et al. who observed comparable safety profiles of biosimilars and the originator during childhood [9]. Since SAEs are rare events, the collection of more data in biologic registers is crucial to draw definite conclusions in the future.

An improvement from baseline was observed in all analyzed parameters (cJADAS10, Physician Global Assessment, number of joints with active arthritis, patient overall well-being, pain and HAQ) after a follow-up of 24 months. Because of the comparatively short treatment period and small number of patients, the results were not statistically significant but at least there was no sign of treatment failure. Cost aspects were the most common reason for switching the biologic therapy from Enbrel® to Benepali®. Since almost one-quarter of patients had an inactive disease at the start of therapy with Benepali®, for these patients, little improvement of the well-controlled disease can be expected, so the observed preservation of this state is also a good outcome.

In adult patients, real-world evidence has so far provided an indication that Benepali® is as effective and safe as the originator in both switched and naïve patients [22]. In Denmark, where there is a mandatory switch recommendation, Glintborg et al. found that the nationwide switch from originator to biosimilar etanercept in 1621 adult patients with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis) had no negative impact on 3 months’ disease activities, and no major safety events were observed [23]. Tweehuysen et al. reported a Dutch cohort of 635 adult patients with non-mandatory transitioning from the originator to Benepali® which showed a slightly lower 6-month treatment persistence rate and smaller decreases in disease activity in the transition cohort compared to the historical cohort, but these differences were not considered clinically relevant [24].

In Germany, automatic substitution is currently not permitted for biologics and biosimilars. As mentioned above, in Denmark, there was a mandatory switch recommendation from the originator Enbrel® to a biosimilar. Due to the introduction of new reference price group for TNF-α blockers including etanercept in Germany, the savings potential for the prescription of an etanercept biosimilar has decreased from about 6000€ to about 200 to 400€ per year and patient (for a weekly therapy with 50mg etanercept) compared to the originator Enbrel® [25]. Glintborg et al. demonstrated that there were no obvious changes in overall use and costs of healthcare services following the switch from originator to biosimilar etanercept [26]. The question of these follow-up costs has not yet been addressed in German patients who are not mandatorily advised to switch.

In summary, a general similarity in efficacy and safety of Benepali® compared to its originator Enbrel® has been shown in the literature and is supported by our data. This will, however, have to be confirmed or refuted by the collection of further data in the future.


Registers such as BiKeR and JuMBO provide valuable data on the safety and efficacy of therapy with DMARD in patients with JIA. To avoid long-term consequences of JIA, therapy with a bDMARD is often necessary. Knowledge of the effectiveness and safety of biologics and biosimilars such as Benepali® is required in order to optimize therapy and patient outcomes and to reduce costs in the health care system in the long term.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.



Adverse event


Antinuclear antibodies


Biologic DMARDs


Biologics in Pediatric Rheumatology Registry


Biosimilar DMARDs


Confidence interval


Clinical Juvenile Arthritis Disease Activity Score


Disease-modifying anti-rheumatic drugs


Health Assessment Questionnaire


Incidence rate


Juvenile idiopathic arthritis


Juvenile arthritis MTX/Biologics long-term Observation


Numerical rating scale


Physician Global Assessment


Serious adverse event


Standard deviation


  1. Giancane G, et al. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187–207.

    Article  Google Scholar 

  2. Minden K, et al. Biologikaregister JuMBO: Langzeitsicherheit von Biologikatherapie bei juveniler idiopathischer arthritis. Z Rheumatol. 2013;72:339–46.

    Article  CAS  Google Scholar 

  3. Horneff G, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638–44.

    Article  CAS  Google Scholar 

  4. Horneff G, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis. 2009;68(4):519–25.

    Article  CAS  Google Scholar 

  5. Armaroli G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther. 2020;22(1):258.

    Article  CAS  Google Scholar 

  6. Horneff G, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.

    Article  Google Scholar 

  7. Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56(suppl_4):iv30–48.

    Article  CAS  Google Scholar 

  8. Gemeinsamer Bundesausschuss. Biologische Arzneimittel: G-BA beschließt Hinweise für eine wirtschaftliche Verordnungsweise von Biologika und Biosimilars; 2020. Available from:

    Google Scholar 

  9. Thiele F, et al. Efficacy and safety of Etanercept Biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study: ACR Open Rheumatol; 2021.

    Google Scholar 

  10. Minden K, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51(8):1407–15.

    Article  CAS  Google Scholar 

  11. Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res. 2017;69(4):552–60.

    Article  CAS  Google Scholar 

  12. Klotsche J, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75(5):855–61.

    Article  CAS  Google Scholar 

  13. Minden K, et al. Time of disease-modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. Arthritis Care Res. 2019;71(4):471–81.

    Article  CAS  Google Scholar 

  14. Meißner Y, et al. Register and cohort studies: overview of the most important data sources at the German rheumatism research center. Z Rheumatol. 2020;79(10):983–95.

    Article  Google Scholar 

  15. Klein A, et al. Biologic therapies in polyarticular juvenile idiopathic arthritis. Comparison of long-term safety data from the German BIKER registry. ACR Open Rheumatol. 2020;2(1):37–47.

    Article  Google Scholar 

  16. Petty RE, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.

    Google Scholar 

  17. Fries JF, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45.

    Article  CAS  Google Scholar 

  18. Consolaro A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66.

    Article  Google Scholar 

  19. Consolaro A, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res. 2014;66(11):1703–9.

    Article  Google Scholar 

  20. ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2); 2016.

    Google Scholar 

  21. Foeldvari I, Becker I, Horneff G. Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry. Arthritis Care Res. 2015;67(11):1529–35.

    Article  CAS  Google Scholar 

  22. Ebbers HC, et al. Real-world evidence on Etanercept biosimilar SB4 in Etanercept-Naïve or switching patients: a systematic review. Rheumatol Ther. 2019;6(3):317–38.

    Article  Google Scholar 

  23. Glintborg B, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192–200.

    Article  Google Scholar 

  24. Tweehuysen L, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheum. 2018;70(9):1408–18.

    Article  CAS  Google Scholar 

  25. (BfArM), B.f.A.u.M. Arzneimittel-Festbeträge; 2021. Available from:

    Google Scholar 

  26. Glintborg B, et al. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019;5(2):e001016.

    Article  Google Scholar 

Download references


We are particularly thankful to the patients who participate in JuMBO. We also thank all physicians, who enrolled more than 5 patients: Prof. Dr. Markus Hufnagel, Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin; Dr. Frank Hamann, Dr. Konrad Boche, Gemeinschaftspraxis für internistische Rheumatologie in Leipzig; Dr. Michael Ortmann, MVZ – Medizinisches Versorgungszentrum Oberberg GmbH; Dr. med. Kirsten Lüthke, Dr. med. Konrad Boche, Schwerpunktpraxis Rheumatologie und Klinische Immunologie in Dresden; Dr. med. Ilka Schwarze, Praxis für internistische Rheumatologie in Leipzig; Prof. Dr. Jörg Henes, Dr. Sebastian Jonas Saur, Universitätsklinikum Tübingen, Zentrum für interdisziplinäre Rheumatologie; Dr. Matthias Kirchgässner, Dr. Martin Sperling, Zentrum für ambulante Rheumatologie in Bruchsal; Dr. Ben Abendroth, Rheumatologie Jena; Dr. med. Gunther Zeh, Rheumatologische Schwerpunktpraxis in Göppingen; Priv. Doz. Dr. Ekkehard Röther, Praxis für Rheumatologie in Donaueschingen; Ilona Jandova, Universitätsklinikum Freiburg, Rheumatologie und Klinische Immunologie; Christina Hillebrecht, Deniz Köksal, Rotes Kreuz Krankenhaus in Bremen, Klinik für internistische Rheumatologie; Dr. Tobias Alexander, Charité – Universitätsmedizin Berlin; Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie; Dr. Wolf Rainer Raub, Rheumatologische Schwerpunktpraxis in Münster; Dr. Katrin Geißler, Praxisgemeinschaft für Rheumatologie und Gastroenterologie in Cottbus; Prof. Dr. Bernhard Hellmich, Dr. Hartmut Mahrhofer, medius Klinik Kirchheim, Klinik für Innere Medizin, Rheumatologie und Immunologie; Dr. Kirsten Karberg, Dr. Henning Christian Brandt, Praxis für Rheumatologie und Innere Medizin in Berlin; Dr. Christine Baumann, Innere Medizin und Rheumatologie in Plauen; Dr. med. Sabine Fasse, Rheumatologikum Hannover; Dr. med. habil. Volker Nehls, St. Elisabeth-Hospital Meerbusch-Lank; Rheinisches Rheuma-Zentrum; Dr. Markus Röser, Dr. Andreas Bruckner, Dr. Sigrid Sonn, Zentrum für interdisziplinäre Rheumatologie Stuttgart, Rheumatologische Schwerpunktpraxis; Dr. Erich Bärlin, Dr. Ekaterina Bauzhadze, Praxis für Rheumatologie und Innere Medizin in Ludwigsburg; Prof. Dr. Martin Aringer, Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden, Bereich Rheumatologie; Prof. Dr. Gernot Keyßer, Dr. Christoph Schäfer, Universitätsklinikum Halle (Saale); Rheumazentrum; Dr. Florian Haas, Rheumatologische Facharztpraxis in Tübingen


Open Access funding enabled and organized by Projekt DEAL. The BiKeR register: Unconditional grant from Abbvie, MSD, Pfizer, Chugai and Roche.

The JuMBO register was or is supported by an unconditional grant from Abbvie, Biogen, BMS, Pfizer, and Roche; the companies had no role in the study design or in the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The JuMBO register was also supported by the Pharmachild project, which was funded by the European Union (grant 260353) within the FP7 framework and by Foreum.

Author information

Authors and Affiliations



KV, KT, JK, and KM contributed to the conception and designed the work. JK analyzed the data. KV, JK, and KM were involved in the interpretation of the data. KV drafted the manuscript. KT, JPH, GH, AK, JK, and KM substantively revised the manuscript. All authors critically revised the manuscript and approved the final submitted draft.

Corresponding author

Correspondence to Kirsten Minden.

Ethics declarations

Ethics approval and consent to participate

Written informed consent was obtained from the patients (age ≥ 18 years) for participation in JuMBO. JuMBO was approved by the Ethics Committee of Charité University Medicine Berlin. JuMBO is conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

KV: No conflict of interest

KT: Advisor Novartis, Pfizer, BMS, research grant support from Novartis and Pfizer

NW: No conflict of interest

GH: Speaking fees and honoraria from Abbvie, Bayer, BMS, Chugai Hexal, MSD, Novartis, Pfizer, Roche, and Swedish Orphan (less than $10,000 each).

AK: Honoraria from Novartis

IF: Advisor and speaking fee from Pfizer

JPH: No conflict of interest

PA: No conflict of interest

GG: Speaking and/or consultant fees from Abbvie, Novartis, Gilead, Lilly

FS: No conflict of interest

PH: Consultant fees, speaking fees, research funding, and/or travel expenses from Pfizer and Biogen

CS: No conflict of interest

ST: Speaking fees and honoraria from Biogen, Pfizer, and Abbvie

ES: None declared

JK: No conflict of interest

KM: Consultant of: GlaxoSmithKline, Sanofi, Speakers bureau: Roche

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vollbach, K., Tenbrock, K., Wagner, N. et al. Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO. Arthritis Res Ther 24, 271 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: